Skip to main content
Premium Trial:

Request an Annual Quote

Danish University Wins $109M Novo Nordisk Grant to Build Proteomics Center

Due in part to an error in the press release on which this article is based, GenomeWeb News  incorrectly reported the award amount. The grant is worth $109.1 million, not $18.2 million.
 
NEW YORK  (GenomeWeb News) — The University of Copenhagen in Denmark plans to use a KRO 600 million ($109.1 million) grant from the Novo Nordisk Foundation to build a center dedicated to protein research, the University said this week.
 
Working with what it said is the largest donation for Danish basic research, the University next year plans to open the Novo Nordisk Foundation Center for Protein Research.
 
The school said the center will “house leading Danish and international protein researchers” and an advanced laboratory for the study of proteins and disease.
 
The grant will allow the university to “boost research into what proteins look like and how they behave and interact in cells and tissues in healthy and sick people,” said Ulla Wewer, dean of the school’s faculty of health Sciences.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.